A detailed history of Chase Investment Counsel Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Chase Investment Counsel Corp holds 7,063 shares of VRTX stock, worth $2.81 Million. This represents 1.11% of its overall portfolio holdings.

Number of Shares
7,063
Previous 8,248 14.37%
Holding current value
$2.81 Million
Previous $3.87 Million 15.05%
% of portfolio
1.11%
Previous 1.38%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$460.0 - $505.78 $545,100 - $599,349
-1,185 Reduced 14.37%
7,063 $3.28 Million
Q2 2024

Aug 02, 2024

BUY
$392.81 - $485.53 $56,957 - $70,401
145 Added 1.79%
8,248 $3.87 Million
Q1 2024

May 02, 2024

BUY
$407.69 - $446.08 $554,050 - $606,222
1,359 Added 20.15%
8,103 $3.39 Million
Q4 2023

Feb 05, 2024

SELL
$343.0 - $410.68 $149,548 - $179,056
-436 Reduced 6.07%
6,744 $2.74 Million
Q3 2023

Nov 08, 2023

BUY
$338.18 - $362.46 $18,599 - $19,935
55 Added 0.77%
7,180 $2.5 Million
Q2 2023

Jul 28, 2023

BUY
$314.42 - $351.91 $45,276 - $50,675
144 Added 2.06%
7,125 $2.51 Million
Q1 2023

May 04, 2023

BUY
$283.23 - $323.1 $22,658 - $25,848
80 Added 1.16%
6,981 $2.2 Million
Q4 2022

Jan 25, 2023

SELL
$285.76 - $321.48 $1.3 Million - $1.46 Million
-4,535 Reduced 39.66%
6,901 $1.99 Million
Q3 2022

Oct 31, 2022

BUY
$273.83 - $305.53 $830,800 - $926,978
3,034 Added 36.11%
11,436 $3.31 Million
Q2 2022

Jul 26, 2022

BUY
$234.96 - $292.55 $1.97 Million - $2.46 Million
8,402 New
8,402 $2.37 Million
Q4 2020

Feb 02, 2021

SELL
$207.01 - $276.09 $2.35 Million - $3.14 Million
-11,375 Closed
0 $0
Q3 2020

Nov 03, 2020

SELL
$255.65 - $303.1 $482,155 - $571,646
-1,886 Reduced 14.22%
11,375 $3.1 Million
Q2 2020

Aug 05, 2020

SELL
$225.48 - $295.8 $681,400 - $893,907
-3,022 Reduced 18.56%
13,261 $3.85 Million
Q1 2020

May 08, 2020

BUY
$199.77 - $247.81 $3.25 Million - $4.04 Million
16,283 New
16,283 $3.87 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Chase Investment Counsel Corp Portfolio

Follow Chase Investment Counsel Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chase Investment Counsel Corp, based on Form 13F filings with the SEC.

News

Stay updated on Chase Investment Counsel Corp with notifications on news.